Monoclonal antibody recognizing cell surface antigen CD14
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 12, 2001
Grant Date -
N/A
app pub date -
Mar 4, 1999
filing date -
Sep 7, 1998
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A monoclonal antibody which recognizes lipopolysaccharide binding site of macrophage cell surface receptor CD14 and has binding activity to monocyte or macrophage cells. The monoclonal antibody suppresses the production of an inflammatory mediator such as TNF, IL-6 or NO at early stages by recognizing CD14, and competitively inhibiting its binding with LPS. Therefore, it is useful for pathology analysis and the treatment of sepsis.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully